OPGN vs. PMD, DMTK, BGLC, NVTA, FRES, ACON, CNTG, TTOO, GNMK, and LH
Should you be buying OpGen stock or one of its competitors? The main competitors of OpGen include Psychemedics (PMD), DermTech (DMTK), BioNexus Gene Lab (BGLC), Invitae (NVTA), Fresh2 Group (FRES), Aclarion (ACON), Centogene (CNTG), T2 Biosystems (TTOO), GenMark Diagnostics (GNMK), and Laboratory Co. of America (LH).
OpGen (NASDAQ:OPGN) and Psychemedics (NASDAQ:PMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, community ranking, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.
In the previous week, Psychemedics had 1 more articles in the media than OpGen. MarketBeat recorded 3 mentions for Psychemedics and 2 mentions for OpGen. Psychemedics' average media sentiment score of 1.29 beat OpGen's score of 0.28 indicating that Psychemedics is being referred to more favorably in the news media.
OpGen received 159 more outperform votes than Psychemedics when rated by MarketBeat users. However, 74.35% of users gave Psychemedics an outperform vote while only 55.64% of users gave OpGen an outperform vote.
Psychemedics has higher revenue and earnings than OpGen. Psychemedics is trading at a lower price-to-earnings ratio than OpGen, indicating that it is currently the more affordable of the two stocks.
2.7% of OpGen shares are owned by institutional investors. Comparatively, 32.1% of Psychemedics shares are owned by institutional investors. 43.8% of OpGen shares are owned by insiders. Comparatively, 24.0% of Psychemedics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
OpGen has a beta of -0.56, suggesting that its stock price is 156% less volatile than the S&P 500. Comparatively, Psychemedics has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500.
Psychemedics has a net margin of -20.23% compared to OpGen's net margin of -852.18%. Psychemedics' return on equity of -59.21% beat OpGen's return on equity.
Summary
Psychemedics beats OpGen on 11 of the 15 factors compared between the two stocks.
Get OpGen News Delivered to You Automatically
Sign up to receive the latest news and ratings for OPGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OPGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
